When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3-ITD AML.

Knight, Tristan E; Ge, Yubin; Taub, Jeffrey W; Hitzler, Johann; Krueger, Joerg

Knight, Tristan E; Ge, Yubin; Taub, Jeffrey W; Hitzler, Johann; Krueger, Joerg.

Affiliation

Knight TE; Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, Ontario, Canada.
Ge Y; Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA.
Taub JW; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Hitzler J; Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, Michigan, USA.
Krueger J; Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA.

Pediatr Blood Cancer ; 68(11): e29278, 2021 11.

Article in En | MEDLINE | ID: mdl-34357678

Subject(s)

Health Services Accessibility; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors/therapeutic use; fms-Like Tyrosine Kinase 3/antagonists & inhibitors; Adult; Child; Humans; Leukemia, Myeloid, Acute/drug therapy; Leukemia, Myeloid, Acute/genetics; Mutation; fms-Like Tyrosine Kinase 3/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Protein Kinase Inhibitors / Fms-Like Tyrosine Kinase 3 / Health Services Accessibility Limits: Adult / Child / Humans Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2021 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google